- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
AbbVie was found in breach of Clause 5.1 after a Venclyxto SPC on EMC showed “Days 1 7” instead of “Days 1-7”…
Third‑party publisher sent repeated Bavencio promotional emails. Panel found promotion was disguised (sender/subject line and poor prominence of sponsorship) and frequency lacked…
PMCPA found multiple breaches on Evolus’ Nuceiva website: no homepage clinical trial signpost, NI prescribing info issues, and mobile display failures (black…
Four patient-facing articles funded by a GSK grant disclosed the funding only at the bottom of each page. PMCPA ruled a narrow…
A UK health professional complained about a Pulse promotional email and linked Eliquis VTE webpages. The email lacked prescribing information and a…
Complaint alleged Roche used a TV newsreader as co-chair to attract delegates, provided hospitality to an unqualified lay person, and promoted MabThera…
Actelion challenged Encysive’s Thelin pilot scheme using credit notes for failed treatment. The Panel found an inducement risk and ruled a breach,…
A Gardasil press release and related PR emails after the UK HPV tender were ruled misleading and exaggerated, including superiority and “vaccine…
A rheumatologist complained that an RCP webcast sponsored by Roche effectively promoted rituximab. The Panel found sponsorship was transparent and arm’s length,…
Procter & Gamble complained that Servier promoted unbalanced messages implying acid suppressants increased fracture risk and reduced bisphosphonate efficacy. The Panel and…
A Champix journal ad claimed significantly greater quit success vs NiQuitin CQ Clear at 12 weeks. The Panel ruled the claim misleading…
A GP practice complained about an Otsuka representative’s unprofessional email (sent from work email) containing disparaging comments about GPs. Breaches were found…
A NeoClarityn journal ad implied clinically supported ‘anti-inflammatory’ action. PMCPA found it inconsistent with the SPC and misleading, breaching Clauses 3.2 and…
A nurse complained a Ferinject brochure implied CosmoFer required a 6-hour infusion, causing anxiety about correct administration. Panel relied on an earlier…
GSK’s ESC 2009 symposium invite was held not to be disguised promotion, but because it referenced ambrisentan it was promotional and needed…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.